Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM DISODIUM VERSENATE vs CUPRIMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Treatment of lead poisoning (including symptomatic and asymptomatic patients with blood lead levels ≥45 μg/d L in children and ≥70 μg/d L in adults),Off-label: treatment of other heavy metal toxicities (e.g., cadmium, chromium, manganese, nickel)
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Not metabolized; excreted unchanged in urine via glomerular filtration and tubular secretion.
Metabolized by oxidation and reduction; primarily renal elimination.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Renal: ~80% as unchanged drug, biliary/fecal: <5%
<5% bound to plasma proteins (albumin)
~70% bound, primarily to serum albumin.
0.2-0.3 L/kg; primarily distributes to extracellular fluid, minimal intracellular penetration
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
IV: 100%; IM: approximately 80-90% (due to local chelation and partial excretion)
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of usual dose; GFR < 10 m L/min: administer 25% of usual dose or consider alternative therapy.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
No specific guidelines available; use with caution and monitor liver function in severe hepatic impairment (Child-Pugh C).
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
25 mg/kg/dose intramuscularly or intravenously every 12 hours for 3-5 days; maximum 1 g/dose.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
Consider renal function; elderly patients often require dose reduction based on creatinine clearance; start at lower end of dosing range and monitor for adverse effects.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
This drug is not indicated for the treatment of iron deficiency anemia or hemochromatosis. Do not use in patients with severe renal impairment. Prolonged or excessive use may lead to toxicities including renal failure, convulsions, and cardiac arrhythmias.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
Renal toxicity: monitor renal function and urine output; avoid excessive doses. Neurotoxicity: can cause tremors, seizures, and encephalopathy, especially with high doses or rapid infusion. Hydration: maintain adequate hydration to promote urinary excretion. Rebound metal mobilization: may transiently increase tissue metal levels. Hypocalcemia: due to calcium displacement; monitor serum calcium. Cardiac effects: risk of arrhythmias, especially with rapid IV administration.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
Absolute: anuria or severe renal failure (creatinine clearance <20 m L/min). Relative: hypersensitivity to edetate salts, pre-existing renal disease, concurrent use with other nephrotoxic drugs.
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
Avoid excessive intake of calcium and vitamin D supplements during therapy (may reduce chelation efficacy). Maintain adequate hydration with water. No specific food restrictions, but a balanced diet is recommended to prevent deficiencies of essential minerals (zinc, copper) that may be chelated.
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fetal zinc/corper deficiency if prolonged use. Avoid unless maternal benefit outweighs risk.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
Excreted into breast milk in low amounts; M/P ratio unknown. Caution due to potential for infant mineral chelation. Use only if clearly needed.
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
No specific dose adjustment required; however, monitor for hypocalcemia and mineral depletion. Increased risk of renal toxicity in pregnancy; ensure adequate hydration.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
Administer deep IM or slow IV infusion (over 2-4 hours) to avoid thrombophlebitis. Monitor urine output and renal function; nephrotoxicity is dose-dependent. Discontinue if oliguria or rising creatinine occurs. For lead encephalopathy, give concurrently with BAL (dimercaprol) to redistribute lead from CNS to blood. Use with caution in patients with pre-existing renal disease, hepatitis, or history of allergic reactions. EDTA can chelate essential metals (zinc, copper) leading to deficiencies during prolonged therapy.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
Report any signs of allergic reaction (rash, itching, difficulty breathing) or injection site pain/swelling immediately.,Drink plenty of fluids (unless instructed otherwise) to help flush out lead through urine.,Avoid taking any other medications, supplements, or over-the-counter products without consulting your doctor, as they may affect treatment.,Do not miss scheduled blood and urine tests; they are essential to monitor lead levels and kidney function.,Severe lead poisoning may cause fatigue, headache, abdominal pain; report these symptoms if they worsen.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM DISODIUM VERSENATE vs CUPRIMINE, answered by our medical review team.
CALCIUM DISODIUM VERSENATE is a Chelating Agent that works by Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.. CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM DISODIUM VERSENATE and CUPRIMINE depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM DISODIUM VERSENATE is: 1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.. The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM DISODIUM VERSENATE and CUPRIMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM DISODIUM VERSENATE is classified as Category C. Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fet. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.